One of the most common sites of cancer metastasis is to the bone. Bone metastasis is associated with substantial morbidity and mortality, and current therapeutic interventions remain largely palliative. Metastasizing tumor cells need to reprogram their metabolic states to adapt to the nutrient environment of distant organs; however, the role and translational relevance of lipid metabolism in bone metastasis remain unclear. Here, we used an in vivo CRISPR activation screening system coupled with positive selection to identify acyl–coenzyme A (CoA) binding protein (ACBP) as a bone metastasis driver. In nonmetastatic and weakly metastatic cancer cells, overexpression of wild-type ACBP, but not the acyl-CoA–binding deficient mutant, stimulated fatty acid oxidation (FAO) and bone metastasis. Conversely, knockout of ACBP in highly bone metastatic cancer cells abrogated metastatic bone colonization. Mechanistically, ACBP-mediated FAO increased ATP and NADPH production, reduced reactive oxygen species, and inhibited lipid peroxidation and ferroptosis. We found that ACBP expression correlated with metabolic signaling, bone metastatic ability, and poor clinical outcomes. In mouse models, pharmacological blockade of FAO or treatment with a ferroptosis inducer inhibited bone metastasis. Together, our findings reveal the role of lipid metabolism in tumor cells adapting and thriving in the bone and identify ACBP as a key regulator of this process. Agents that target FAO or induce ferroptosis represent a promising therapeutic approach for treating bone metastases.
B7-H3/CD276 is an emerging immunotherapy target in cancers. However, limited knowledge of B7-H3 signaling and its role in modulating the tumor microenvironment hinders the clinical application of B7-H3–targeting therapy. In this study, we report that B7-H3 plays dual roles in regulating myeloid-derived suppressor cells (MDSC) and cancer-associated fibroblasts (CAF), thereby promoting tumor progression and therapy resistance, respectively. We comprehensively characterized a noncanonical function of B7-H3 that triggers MAPK signaling in monocytic MDSCs (M-MDSC) and induces cellular senescence. The senescent M-MDSCs secreted chemokines to recruit immunosuppressive granulocytic MDSCs (Gr-MDSC). Genetic deletion or pharmacologic inhibition of B7-H3/CD276 reduced Gr-MDSCs and delayed tumor progression. Nevertheless, the secretory factor SPINK1 derived from MDSCs compensatorily activates EGFR/MEK/ERK signaling in CAFs and promotes their extracellular matrix remodeling features, dampening B7-H3–targeting immunotherapy. Combining the B7-H3 monoclonal antibody with the FDA-approved MEK inhibitor trametinib showed durable antitumor effects in preclinical models of castration-resistant prostate cancer by fully attenuating immunosuppressive mechanisms. Significance: Our studies uncovered a long-unknown B7-H3 signaling that orchestrates the cross-talk of cancer cells with myeloid and stromal cells in the host and provided novel mechanistic insights and effective combinatorial strategies for B7-H3–targeting immunotherapy in advanced prostate cancer among other malignancies.